Quarterly report pursuant to Section 13 or 15(d)

Royalty and licensing income

v2.4.0.6
Royalty and licensing income
9 Months Ended
Apr. 30, 2012
Royality And Licensing Income [Text Block]

Note 11 – Royalty and licensing income


The Company has a license agreement with QIAGEN Gaithersburg Inc. (“Qiagen”) that began in 2005, whereby the Company earns quarterly running royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended April 30, 2012 and 2011, the Company recorded royalty income under the Agreement of approximately $1.1 million. During the nine months ended April 30, 2012 and 2011, the Company recorded royalty income under the Agreement of approximately $4.3 million and $4.8 million, respectively.


On April 27, 2007 (the “Effective Date”) Enzo Life Sciences, Inc. (“Life Sciences”) and Abbott Molecular Inc. (“Abbott”) entered into a 5 year agreement, covering the supply of certain of Enzo Life Sciences products to Abbott for use in their product line. The parties also entered into a limited non-exclusive royalty bearing cross-licensing agreement (“Licensing Agreement”) for various patents. The Licensing Agreement requires each party to pay royalties, as defined through the lives of the related non-expired patents. During the nine months ended April 30, 2011, the Company recorded royalty income of $0.5 million under the Licensing Agreement. In January 2011, Abbott notified the Company that they have made a final royalty payment because they are unaware of any non-expired patents.